These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
440 related articles for article (PubMed ID: 27686810)
1. Proteogenomics for the Study of Gastrointestinal Stromal Tumors. Kondo T Adv Exp Med Biol; 2016; 926():139-151. PubMed ID: 27686810 [TBL] [Abstract][Full Text] [Related]
2. Identifying Secondary Mutations in Chinese Patients with Imatinib-Resistant Gastrointestinal Stromal Tumors (GISTs) by Next Generation Sequencing (NGS). Du J; Wang S; Wang R; Wang SY; Han Q; Xu HT; Yang P; Liu Y Pathol Oncol Res; 2020 Jan; 26(1):91-100. PubMed ID: 31758409 [TBL] [Abstract][Full Text] [Related]
3. The role of KIT in the management of patients with gastrointestinal stromal tumors. Hornick JL; Fletcher CD Hum Pathol; 2007 May; 38(5):679-87. PubMed ID: 17437861 [TBL] [Abstract][Full Text] [Related]
4. Personalized Medicine in Gastrointestinal Stromal Tumor (GIST): Clinical Implications of the Somatic and Germline DNA Analysis. Ravegnini G; Nannini M; Sammarini G; Astolfi A; Biasco G; Pantaleo MA; Hrelia P; Angelini S Int J Mol Sci; 2015 Jul; 16(7):15592-608. PubMed ID: 26184165 [TBL] [Abstract][Full Text] [Related]
5. [Molecular and genetic features of gastrointestinal stromal tumors (GIST)]. Buleje S J; Yábar B A; Guevara-Fujita M; Fujita R Rev Gastroenterol Peru; 2012; 32(4):394-9. PubMed ID: 23307090 [TBL] [Abstract][Full Text] [Related]
7. [The importance of mutational status in prognosis and therapy of GIST]. Comandone A; Boglione A Recenti Prog Med; 2015 Jan; 106(1):17-22. PubMed ID: 25621775 [TBL] [Abstract][Full Text] [Related]
8. Hedgehog pathway dysregulation contributes to the pathogenesis of human gastrointestinal stromal tumors via GLI-mediated activation of KIT expression. Tang CM; Lee TE; Syed SA; Burgoyne AM; Leonard SY; Gao F; Chan JC; Shi E; Chmielecki J; Morosini D; Wang K; Ross JS; Kendrick ML; Bardsley MR; Siena M; Mao J; Harismendy O; Ordog T; Sicklick JK Oncotarget; 2016 Nov; 7(48):78226-78241. PubMed ID: 27793025 [TBL] [Abstract][Full Text] [Related]
9. Dual Targeting of Insulin Receptor and KIT in Imatinib-Resistant Gastrointestinal Stromal Tumors. Chen W; Kuang Y; Qiu HB; Cao Z; Tu Y; Sheng Q; Eilers G; He Q; Li HL; Zhu M; Wang Y; Zhang R; Wu Y; Meng F; Fletcher JA; Ou WB Cancer Res; 2017 Sep; 77(18):5107-5117. PubMed ID: 28760855 [TBL] [Abstract][Full Text] [Related]
10. [Molecular mechanism and therapeutic strategy for resistance to tyrosine kinase inhibitors in targeted treatment of gastrointestinal stromal tumors]. Xu J; Cao H Zhonghua Wei Chang Wai Ke Za Zhi; 2013 Mar; 16(3):288-91. PubMed ID: 23536353 [TBL] [Abstract][Full Text] [Related]
19. Clinical significance of oncogenic KIT and PDGFRA mutations in gastrointestinal stromal tumours. Lasota J; Miettinen M Histopathology; 2008 Sep; 53(3):245-66. PubMed ID: 18312355 [TBL] [Abstract][Full Text] [Related]
20. KIT over-expression by p55PIK-PI3K leads to Imatinib-resistance in patients with gastrointestinal stromal tumors. Lai S; Wang G; Cao X; Luo X; Wang G; Xia X; Hu J; Wang J Oncotarget; 2016 Jan; 7(2):1367-79. PubMed ID: 26587973 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]